NASDAQ:CUR - Neuralstem Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.17 -0.04 (-3.31 %) (As of 07/20/2018 04:00 PM ET)Previous Close$1.21Today's Range$1.17 - $1.2452-Week Range$0.88 - $6.05Volume10,800 shsAverage Volume175,316 shsMarket Capitalization$18.19 millionP/E RatioN/ADividend YieldN/ABeta1.48 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Receive CUR News and Ratings via Email Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:CUR CUSIPN/A Webwww.neuralstem.com Phone301-366-4841 Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales68.22 Cash FlowN/A Price / CashN/A Book Value$0.56 per share Price / Book2.09 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-15,660,000.00 Net Margins-5,281.44% Return on Equity-119.42% Return on Assets-74.71% Miscellaneous Employees6 Outstanding Shares15,160,000Market Cap$18.19 Neuralstem (NASDAQ:CUR) Frequently Asked Questions What is Neuralstem's stock symbol? Neuralstem trades on the NASDAQ under the ticker symbol "CUR." How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) released its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter. Neuralstem had a negative net margin of 5,281.44% and a negative return on equity of 119.42%. View Neuralstem's Earnings History. What price target have analysts set for CUR? 0 equities research analysts have issued twelve-month price objectives for Neuralstem's shares. Their forecasts range from $1.91 to $1.91. On average, they anticipate Neuralstem's stock price to reach $1.91 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price. View Analyst Ratings for Neuralstem. What is the consensus analysts' recommendation for Neuralstem? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuralstem in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Neuralstem's key competitors? Some companies that are related to Neuralstem include Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), BioCardia (BCDA), Aevi Genomic Medicine (GNMX), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), Arsanis (ASNS), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Microbot Medical (MBOT), Oncobiologics (ONS), aTyr Pharma (LIFE), Vical (VICL) and Vaxart (VXRT). Who are Neuralstem's key executives? Neuralstem's management team includes the folowing people: Mr. Richard J. Daly, Chairman, Pres, CEO & CFO (Age 57)Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 58)Dr. Thomas G. Hazel Ph.D., Sr. VP of ResearchDr. David P. Recker, Chief Medical Officer (Age 60) Has Neuralstem been receiving favorable news coverage? Media stories about CUR stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neuralstem earned a news sentiment score of 0.02 on Accern's scale. They also assigned news articles about the company an impact score of 45.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of Neuralstem? Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neuralstem's stock price today? One share of CUR stock can currently be purchased for approximately $1.17. How big of a company is Neuralstem? Neuralstem has a market capitalization of $18.19 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe. How can I contact Neuralstem? Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected] MarketBeat Community Rating for Neuralstem (NASDAQ CUR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 200 (Vote Outperform)Underperform Votes: 165 (Vote Underperform)Total Votes: 365MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?